UNASSIGNED: e18063 Background: Despite a number of effective first-line regimens, virtually all @entity1 (pts) with advanced NSCLC will relapse. A second line therapy with @entity1205 or pemetrexed, according to @entity5 histotype, represents the standard treatment for pts with a good performance status (PS). The introduction of @entity4149 kinase inhibitors (TKIs) for pre-treated NSCLC pts have added a valid option in this setting. METHODS: We have analyzed outcome data of 85 NSCLC pts (table), who received after a @entity902 -based chemotherapy, a second-line therapy with @entity1205 , pemetrexed, @entity3866 or @entity4562 (expanded access program), in order to assess and compare their efficacy and tolerability in this setting. RESULTS: As regards chemotherapy, pemetrexed was superior to @entity1205 in all measures (RR 45% vs 5 %, TTP 5.5 vs 4.5 months, median survival 13.8 vs 9.9 months), but only RR was statistically significant (p=0.003). @entity4562 obtained a better TTP and @entity3012 than @entity3866 , although the differences were not statistically significant (7.9 vs 7.6 months; 15.4 vs 13.3 months respectively). But, RR was more relevant for @entity3866 (29.2% vs 15% (p=0.2), even if an increased number of disease stabilization was recorded for @entity4562 (65% vs 29.1%). Significant differences were observed in RR between pemetrexed and @entity4562 (p=0.03) and @entity3866 and @entity1205 (p=0.03). All @entity137 recorded were manageable. CONCLUSIONS: In our study, TKIs, above all @entity4562 , seem to be a favourable choice for second line treatment, obtaining good response rates, with important stabilizations of disease and a relevant median survival, not strictly related to the histotype. Neverthless, for non squamous pts pemetrexed remains an important therapeutic choice. [Table: see text].

Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or XXXX kinase inhibitors? Our experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib', 'Gefitinib'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity4149 :: (D014443,Chemical) :: ['tyrosine']
